The combined ratio sits below 100% for the latest quarter, which implies a modest underwriting profit, but the margin of safety is thin at roughly 3.3 points. The loss ratio has drifted from 84.4% in 2026Q1 to 86.3% in 2026Q3, suggesting medical cost pressure is building again even as expense discipline held the expense ratio near 10.5%. Investors should monitor whether this loss ratio trend persists, since it appears to be the main driver of underwriting sensitivity.

An ROE in the low single digits suggests that investment income on float is not fully offsetting thin underwriting margins of 3.3%. The sequential decline from 3.8% to 2.7% indicates that earnings momentum has softened despite the headline beat, which may reflect non-recurring items rather than durable improvement. Relative to UnitedHealth and Cigna, whose ROE sits near 15%, CVS generates substantially less return per dollar of equity.

The gap between trailing and forward P/E implies the market expects trailing earnings, distorted by prior reserve charges and the 2025Q3 loss, to normalize materially. A P/B of 1.41 is modest relative to UNH at 3.53, which suggests the market is applying a conglomerate discount tied to skepticism about integration synergies. Investors should treat the valuation as contingent on sustained combined ratios below 100%.

The deleveraging trend is constructive, but a D/E near 0.93 still leaves less capacity to absorb an adverse reserve or utilization shock than peers at roughly 0.75. Interest coverage of 4.81 times is adequate but well below the 6 times level seen in 2026Q2, suggesting the recent earnings softness has tightened the buffer. The leverage profile warrants monitoring as a constraint on capital deployment.